Kevin Michael Lundquist
CIK: 0002074701
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Lundquist Kevin Michael
Lundquist Kevin Michael (SEC CIK 0002074701) files insider reports with the SEC as Chief Financial Officer of Outlook Therapeutics, Inc. (OTLK) and Chief Financial Officer of CapsoVision, Inc (CV).
Signal8 holds 3 ownership filings by Lundquist Kevin Michael (2 Form 3, 1 Form 4), filed between Jul 1, 2025 and Sep 2, 2026. Those filings report 1 transaction, the latest on Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lundquist Kevin Michael's filings is in ISELIN, NJ.
Recent filings by Lundquist Kevin Michael
- Sep 1, 2026: Grant or award of OTLK derivative securities (Form 4, code A).
Other insiders filing for Outlook Therapeutics, Inc. (OTLK)
- Jahr Robert Charles, Chief Executive Officer
- Sukhtian Ghiath M., Director
- KENYON LAWRENCE A, Chief Financial Officer
- Sukhtian Faisal Ghiath, Director
- Haddadin Yezan Munther, Director
- THURMAN RANDY H, Director